Ki-67 is a strong prognostic marker of non-small cell lung cancer when tissue heterogeneity is considered

BMC Clinical Pathology

Volumn 14, Issue 1, 2014, Pages

  Tabata, Kazuhiro ^a,b   Tanaka, Tomonori ^a,b   Hayashi, Tomayoshi ^b   Hori, Takashi ^c,d   Nunomura, Sayuri ^a,b   Yonezawa, Suguru ^e   Fukuoka, Junya ^a,b  

^a NAGASAKI UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^c Department of Surgical Pathology Laboratory of Pathology   (Japan)

^d TOYAMA UNIVERSITY HOSPITAL   (Japan)

^e KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Biomarkers; Expression; Lung cancer; Pathology; Tissue heterogeneity; Tissue microarray

Indexed keywords

BIOLOGICAL MARKER; KI 67 ANTIGEN; PARAFFIN;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; FEMALE; FOLLOW UP; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; SPIRAL ARRAY; SURVIVAL TIME; TISSUE MICROARRAY; VERY ELDERLY;

EID: 84901632661     PISSN: None     EISSN: 14726890     Source Type: Journal    
DOI: 10.1186/1472-6890-14-23     Document Type: Article

References (22)

1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, Int J Cancer 2010 127 12 2893 2917 10.1002/ijc.25516 21351269
2. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H, J immunol 1984 133 4 1710 1715 6206131 (Pubitemid 14035254)
3. Proliferation index as a prognostic marker in breast cancer. Veronese SM, Gambacorta M, Gottardi O, Scanzi F, Ferrari M, Lampertico P, Cancer 1993 71 12 3926 3931 10.1002/1097-0142(19930615)71:12<3926::AID-CNCR2820711221>3.0. CO;2-2 8508358 (Pubitemid 23172971)
4. Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Miyake H, Muramaki M, Kurahashi T, Takenaka A, Fujisawa M, Urol Oncol 2010 28 2 145 151 10.1016/j.urolonc.2008.08.001 18848789
5. Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumors. Pfister C, Lacombe L, Vezina MC, Moore L, Larue H, Tetu B, Meyer F, Fradet Y, Hum Pathol 1999 30 11 1350 1355 10.1016/S0046-8177(99)90067-9 10571516 (Pubitemid 29534298)
6. Ki-67 expression in axillary lymph node metastases in breast cancer is prognostically significant. Tawfik K, Kimler BF, Davis MK, Fan F, Tawfik O, Hum Pathol 2013 44 1 39 46 10.1016/j.humpath.2012.05.007 22939959
7. Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining. Jamali M, Chetty R, Endocr Pathol 2008 19 4 282 288 10.1007/s12022-008-9044-0 18931958
8. Heterogeneity of immunostaining for tumour markers in non-small cell lung carcinoma. Macdonald C, Michael A, Colston K, Mansi J, European J Cancer 2004 40 3 461 466 10.1016/j.ejca.2003.10.019 (Pubitemid 38121285)
9. Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors. Couvelard A, Deschamps L, Ravaud P, Baron G, Sauvanet A, Hentic O, Colnot N, Paradis V, Belghiti J, Bedossa P, Ruszniewski P, Mod Pathol: an official Jof the United States and Canadian Academy of Pathology, Inc 2009 22 2 273 281 10.1038/modpathol.2008.177
10. Lung adenocarcinoma with mixed bronchioloalveolar and invasive components: clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization. Terasaki H, Niki T, Matsuno Y, Yamada T, Maeshima A, Asamura H, Hayabuchi N, Hirohashi S, Am J Surg Pathol 2003 27 7 937 951 10.1097/00000478-200307000-00009 12826886 (Pubitemid 36758897)
11. Spiral array: a new high-throughput technology covers tissue heterogeneity. Fukuoka J, Hofer MD, Hori T, Tanaka T, Ishizawa S, Nomoto K, Saito M, Uemura T, Chirieac LR, Arch Pathol Lab Med 2012 136 11 1377 1384 10.5858/arpa.2011-0393-OA 23106583
12. Patohology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart Lyon: IARC Press, Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, 2004
13. Application of a new technique, spiral tissue microarrays constructed using needle biopsy specimens, to prostate cancer research. Komiya A, Kato T, Hori T, Fukuoka J, Yasuda K, Fuse H, Komiya A, Kato T, Hori T, Fukuoka J, Yasuda K, Fuse H, Int J Oncol 2014 44 1 195 202 24220327
14. Ki-67 expression and prognosis for smokers with resected stage I non-small cell lung cancer. Haga Y, Hiroshima K, Iyoda A, Shibuya K, Shimamura F, Iizasa T, Fujisawa T, Ohwada H, Ann Thorac Surg 2003 75 6 1727 1732 discussion 1732-1723 10.1016/S0003-4975(03)00119-X 12822607 (Pubitemid 36677202)
15. Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers. Hommura F, Dosaka-Akita H, Mishina T, Nishi M, Kojima T, Hiroumi H, Ogura S, Shimizu M, Katoh H, Kawakami Y, Clin Cancer Res 2000 6 10 4073 4081 11051259
16. Clinicopathologic factors influencing postoperative prognosis in patients with small-sized adenocarcinoma of the lung. Inoue M, Takakuwa T, Minami M, Shiono H, Utsumi T, Kadota Y, Nasu T, Aozasa K, Okumura M, J Thorac Cardiovas Surg 2008 135 4 830 836 10.1016/j.jtcvs.2007.10.034 (Pubitemid 351417932)
17. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. Takano T, Fukui T, Ohe Y, Tsuta K, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Furuta K, Tamura T, J Clin Oncol: official journal of the American Society of Clinical Oncology 2008 26 34 5589 5595 10.1200/JCO.2008.16.7254
18. ROS1 rearrangements define a unique molecular class of lung cancers. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ, J Clin Oncol 2012 30 8 863 870 10.1200/JCO.2011.35.6345 22215748
19. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF, International Ki-67 in Breast Cancer Working G, J Nat Cancer Inst 2011 103 22 1656 1664 10.1093/jnci/djr393 21960707
20. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S, Pancreas 2010 39 6 707 712 10.1097/MPA.0b013e3181ec124e 20664470
21. Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue. Potts SJ, Krueger JS, Landis ND, Eberhard DA, Young GD, Schmechel SC, Lange H, Lab Invest 2012 92 9 1342 1357 10.1038/labinvest.2012.91 22801299
22. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G, N Engl J Med 2007 356 8 800 808 10.1056/NEJMoa065411 17314339 (Pubitemid 46294612)